Mechanisms and control of protein translation in the kidney

American Journal of Nephrology

Volumn 31, Issue 3, 2010, Pages 189-201

  Schaeffer, Valerie ^b,c   Abrass, Christine K ^a,c,d  

^a Vet Aff Puget Sound Hlth Care S   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Diabetic nephropathy; MicroRNA; MTOR; Nephritis; Nephropathy; Polycystic kidney disease; Protein synthesis; Renal cancer; Translational control

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; RNA;

CELL SURVIVAL; DIABETIC NEPHROPATHY; DOWN REGULATION; ENZYME REGULATION; GENE INACTIVATION; KIDNEY; KIDNEY CANCER; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MITOSIS; NEPHRITIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RNA TRANSCRIPTION;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; KIDNEY; KIDNEY DISEASES; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION;

EID: 72149112785     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000268954     Document Type: Review

References (113)

1. Leung AK, Sharp PA: MicroRNAs: A safeguard against turmoil? Cell 2007; 130: 581-585.
2. Anderson P, Kedersha N: Stress granules. Curr Biol 2009; 19:R397-R398.
3. Sonenberg N, Hinnebusch AG: Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell 2009; 136: 731-745.
4. Ceci M, Gaviraghi C, Gorrini C, Sala LA, Offenhauser N, Marchisio PC, Biffo S: Release of eif6 (p27bbp) from the 60s subunit allows 80s ribosome assembly. Nature 2003; 426: 579-584.
5. Chendrimada TP, Finn KJ, Ji X, Baillat D, Gregory RI, Liebhaber SA, Pasquinelli AE, Shiekhattar R: MicroRNA silencing through risc recruitment of eif6. Nature 2007; 447: 823-828.
6. Kozak M: Circumstances and mechanisms of inhibition of translation by secondary structure in eucaryotic mRNAs. Mol Cell Biol 1989; 9: 5134-5142.
7. Kozak M: An analysis of 5-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987; 15: 8125-8148.
8. Bhandari BK, Feliers D, Duraisamy S, Stewart JL, Gingras AC, Abboud HE, Choudhury GG, Sonenberg N, Kasinath BS: Insulin regulation of protein translation repressor 4ebp1, an eif4e-binding protein, in renal epithelial cells. Kidney Int 2001; 59: 866-875.
9. Mariappan MM, Shetty M, Sataranatarajan K, Choudhury GG, Kasinath BS: Glycogen synthase kinase 3beta is a novel regulator of high glucose- and high insulin-induced extracellular matrix protein synthesis in renal proximal tubular epithelial cells. J Biol Chem 2008; 283: 30566-30575.
10. Stoneley M, Willis AE: Cellular internal ribosome entry segments: Structures, transacting factors and regulation of gene expression. Oncogene 2004; 23: 3200-3207.
11. Morris DR, Geballe AP: Upstream open reading frames as regulators of mRNA translation. Mol Cell Biol 2000; 20: 8635-8642.
12. Sachs MS, Geballe AP: Downstream control of upstream open reading frames. Genes Dev 2006; 20: 915-921.
13. Holcik M, Sonenberg N: Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 2005; 6: 318-327.
14. Wek RC, Jiang HY, Anthony TG: Coping with stress: Eif2 kinases and translational control. Biochem Soc Trans 2006; 34: 7-11.
15. Spriggs KA, Stoneley M, Bushell M, Willis AE: Re-programming of translation following cell stress allows ires-mediated translation to predominate. Biol Cell 2008; 100: 27-38.
16. Yamasaki S, Anderson P: Reprogramming mRNA translation during stress. Curr Opin Cell Biol 2008; 20: 222-226.
17. Kimball SR, Horetsky RL, Ron D, Jefferson LS, Harding HP: Mammalian stress granules represent sites of accumulation of stalled translation initiation complexes. Am J Physiol Cell Physiol 2003; 284:C273-C284.
18. Scott BA, Avidan MS, Crowder CM: Regulation of hypoxic death in C. elegans by the insulin/ IgF receptor homolog daf-2. Science 2002; 296: 2388-2391.
19. Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, Delia D, Capaccioli S, Nicolin A: Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by akt. Oncogene 2004; 23: 5781-5791.
20. Lamitina ST, Strange K: Transcriptional targets of daf-16 insulin signaling pathway protect C. elegans from extreme hypertonic stress. Am J Physiol Cell Physiol 2005; 288: C467-C474.
21. Patel PH, Tamanoi F: Increased rheb-tor signaling enhances sensitivity of the whole organism to oxidative stress. J Cell Sci 2006; 119: 4285-4292.
22. Nairn AC, Matsushita M, Nastiuk K, Horiuchi A, Mitsui K, Shimizu Y, Palfrey HC: Elongation factor-2 phosphorylation and the regulation of protein synthesis by calcium. Prog Mol Subcell Biol 2001; 27: 91-129.
23. Meister G: MiRNAs get an early start on translational silencing. Cell 2007; 131: 25-28.
24. Kloosterman WP, Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-450.
25. Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity: Micro- RNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228-234.
26. Thermann R, Hentze MW: Drosophila mir2 induces pseudo-polysomes and inhibits translation initiation. Nature 2007; 447: 875-878.
27. Cannell IG, Kong YW, Bushell M: How do microRNAs regulate gene expression? Biochem Soc Trans 2008; 36: 1224-1231.
28. Saal S, Harvey SJ: MicroRNAs and the kidney: coming of age. Curr Opin Nephrol Hypertens 2009; 18: 317-323.
29. Ha TS, Barnes JL, Stewart JL, Ko CW, Miner JH, Abrahamson DR, Sanes JR, Kasinath BS: Regulation of renal laminin in mice with type ii diabetes. J Am Soc Nephrol 1999; 10: 1931-1939.
30. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Feliers D: mRNA translation: unexplored territory in renal science. J Am Soc Nephrol 2006; 17: 3281-3292.
31. Mariappan MM, Feliers D, Mummidi S, Choudhury GG, Kasinath BS: High glucose, high insulin, and their combination rapidly induce laminin-beta1 synthesis by regulation of mRNA translation in renal epithelial cells. Diabetes 2007; 56: 476-485.
32. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, Barnes JL, Kasinath BS: Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am J Pathol 2007; 171: 1733-1742.
33. Inoki K: Role of TSC-mTOR pathway in diabetic nephropathy. Diabetes Res Clin Pract 2008; 82(suppl 1):S59-S62.
34. Ha H, Hwang IA, Park JH, Lee HB: Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 2008; 82(suppl 1):S42-S45.
35. Lindenmeyer MT, Rastaldi MP, Ikehata M, Neusser MA, Kretzler M, Cohen CD, Schlondorff D: Proteinuria and hyperglycemia induce endoplasmic reticulum stress. J Am Soc Nephrol 2008; 19: 2225-2236.
36. Inagi R: Endoplasmic reticulum stress in the kidney as a novel mediator of kidney injury. Nephron Exp Nephrol 2009; 112:e1-e9.
37. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A: Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 2006; 340: 296-301.
38. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J: Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007; 27: 495-502.
39. Zdychova J, Vesela J, Kazdova L, Komers R: Renal activity of akt kinase in experimental type 1 diabetes. Physiol Res 2007; 57: 709-715.
40. Teshima-Kondo S, Kondo K, Prado-Lourenco L, Gonzalez-Herrera IG, Rokutan K, Bayard F, Arnal JF, Prats AC: Hyperglycemia upregulates translation of the fibroblast growth factor 2 mRNA in mouse aorta via internal ribosome entry site. FASEB J 2004; 18: 1583-1585.
41. Gonzalez-Herrera IG, Prado-Lourenco L, Teshima-Kondo S, Kondo K, Cabon F, Arnal JF, Bayard F, Prats AC: Ires-dependent regulation of fgf-2 mRNA translation in pathophysiological conditions in the mouse. Biochem Soc Trans 2006; 34: 17-21.
42. Griffin E, Re A, Hamel N, Fu C, Bush H, Mc- Caffrey T, Asch AS: A link between diabetes and atherosclerosis: glucose regulates expression of cd36 at the level of translation. Nat Med 2001; 7: 840-846.
43. Lowe WL Jr, Florkiewicz RZ, Yorek MA, Spanheimer RG, Albrecht BN: Regulation of growth factor mRNA levels in the eyes of diabetic rats. Metabolism 1995; 44: 1038.
44. Vasko R, Koziolek M, Ikehata M, Rastaldi MP, Jung K, Schmid H, Kretzler M, Muller GA, Strutz F: Role of basic fibroblast growth factor (fgf-2) in diabetic nephropathy and mechanisms of its induction by hyperglycemia in human renal fibroblasts. Am J Physiol Renal Physiol 2009; 296:F1452-F1463.
45. Sourris KC, Forbes JM: Interactions between advanced glycation end-products (age) and their receptors in the development and progression of diabetic nephropathy: are these receptors valid therapeutic targets. Curr Drug Targets 2009; 10: 42-50.
46. Shi Y, Taylor SI, Tan SL, Sonenberg N: When translation meets metabolism: multiple links to diabetes. Endocr Rev 2003; 24: 91-101.
47. Taneda S, Pippin JW, Sage EH, Hudkins KL, Takeuchi Y, Couser WG, Alpers CE: Amelioration of diabetic nephropathy in SPARCnull mice. J Am Soc Nephrol 2003; 14: 968-980.
48. Wolf G, Schanze A, Stahl RA, Shankland SJ, Amann K: P27(kip1) knockout mice are protected from diabetic nephropathy: evidence for p27(kip1) haplotype insufficiency. Kidney Int 2005; 68: 1583-1589.
49. Petz M, Kozina D, Huber H, Siwiec T, Seipelt J, Sommergruber W, Mikulits W: The leader region of laminin b1 mRNA confers cap-independent translation. Nucleic Acids Res 2007; 35: 2473-2482.
50. Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz- Vega S, Yonezawa K: Insulin and aminoacid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene 2006; 25: 6361-6372.
51. Lloberas N, Cruzado JM, Franquesa M, Herrero- Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395-1404.
52. Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R, Guan KL, Yoshimura A: The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun 2009; 384: 471-475.
53. Wittmann S, Daniel C, Stief A, Vogelbacher R, Amann K, Hugo C: Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation 2009; 87: 1290-1299.
54. Wang Q, Wang Y, Minto AW, Wang J, Shi Q, Li X, Quigg RJ: MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008; 22: 4126-4135.
55. Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, Natarajan R: MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of e-box repressors. Proc Natl Acad Sci USA 2007; 104: 3432-3437.
56. Abrass CK, Spicer D, Berfield AK, St John PL, Abrahamson DR: Diabetes induces changes in glomerular development and laminin-beta 2 (s-laminin) expression. Am J Pathol 1997; 151: 1131-1140.
57. Schaeffer V, Hansen KM, Morris DR, Abrass CK: Reductions in laminin {beta}2 mRNA translation are responsible for impaired IgFbp-5-mediated mesangial cell migration in the presence of high glucose. Am J Physiol Renal Physiol 2009;in press.
58. Pierson M, Cordier J, Hervouuet F, Rauber G: An unusual congenital and familial congenital malformative combination involving the eye and kidney. J Genet Hum 1963; 12: 184-213.
59. Zenker M, Aigner T, Wendler O, Tralau T, Muntefering H, Fenski R, Pitz S, Schumacher V, Royer-Pokora B, Wuhl E, Cochat P, Bouvier R, Kraus C, Mark K, Madlon H, Dotsch J, Rascher W, Maruniak-Chudek I, Lennert T, Neumann LM, Reis A: Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet 2004; 13: 2625-2632.
60. Zenker M, Tralau T, Lennert T, Pitz S, Mark K, Madlon H, Dotsch J, Reis A, Muntefering H, Neumann LM: Congenital nephrosis, mesangial sclerosis, and distinct eye abnormalities with microcoria: an autosomal recessive syndrome. Am J Med Genet [A] 2004; 130A:138-145.
61. Zenker M, Pierson M, Jonveaux P, Reis A: Demonstration of two novel lamb2 mutations in the original Pierson syndrome family reported 42 years ago. Am J Med Genet A 2005; 138: 73-74.
62. Jarad G, Cunningham J, Shaw AS, Miner JH: Proteinuria precedes podocyte abnormalities in lamb2-/- mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest 2006; 116: 2272-2279.
63. Kato M, Arce L, Natarajan R: MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol 2009; 4: 1255-1266.
64. Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, Gunn A, Nakagawa Y, Shimano H, Todorov I, Rossi JJ, Natarajan R: TGF-beta activates akt kinase through a microRNAdependent amplifying circuit targeting PTEN. Nat Cell Biol 2009; 11: 881-889.
65. Abrass CK, Peterson CV, Raugi GJ: Phenotypic expression of collagen types in mesangial matrix of diabetic and nondiabetic rats. Diabetes 1988; 37: 1695-1702.
66. Abrass CK, Spicer D, Raugi GJ: Insulin induces a change in extracellular matrix glycoproteins synthesized by rat mesangial cells in culture. Kidney Int 1994; 46: 613-620.
67. Abrass CK: Diabetic nephropathy: mechanisms of mesangial matrix expansion. West J Med 1995; 162: 318-321.
68. Abrass CK, Spicer D, Raugi GJ: Induction of nodular sclerosis by insulin in rat mesangial cells in vitro: studies of collagen. Kidney Int 1995; 47: 25-37.
69. Sivan G, Elroy-Stein O: Regulation of mRNA translation during cellular division. Cell Cycle 2008; 7: 741-744.
70. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP: Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007; 177: 346-352.
71. Yilmaz M, Christofori G: Emt, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28: 15-33.
72. Raught B, Gingras AC: Eif4e activity is regulated at multiple levels. Int J Biochem Cell Biol 1999; 31: 43-57.
73. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL: Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
74. Sola-Villa D, Camacho M, Sola R, Soler M, Diaz JM, Vila L: IL-1beta induces VEGF, independently of PGE2 induction, mainly through the PI3-K/mTOR pathway in renal mesangial cells. Kidney Int 2006; 70: 1935-1941.
75. Hudes GR: Targeting mTOR in renal cell carcinoma. Cancer 2009; 115: 2313-2320.
76. Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K: A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008; 68: 2934-2943.
77. Woodard J, Sassano A, Hay N, Platanias LC: Statin-dependent suppression of the akt/ mammalian target of rapamycin signaling cascade and programmed cell death 4 upregulation in renal cell carcinoma. Clin Cancer Res 2008; 14: 4640-4649.
78. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M: Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of mir-141 and mir-200c. J Pathol 2008; 216: 418-427.
79. Heicappell R: Cadherins in renal cell carcinoma. Anticancer Res 1999; 19: 1501-1504.
80. Cavallaro U, Christofori G: Cell adhesion and signalling by cadherins and Ig-cams in cancer. Nat Rev Cancer 2004; 4: 118-132.
81. Dutta KK, Zhong Y, Liu YT, Yamada T, Akatsuka S, Hu Q, Yoshihara M, Ohara H, Takehashi M, Shinohara T, Masutani H, Onuki J, Toyokuni S: Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci 2007; 98: 1845-1852.
82. Wilson PD: Polycystic kidney disease: new understanding in the pathogenesis. Int J Biochem Cell Biol 2004; 36: 1868-1873.
83. Yoder BK, Mulroy S, Eustace H, Boucher C, Sandford R: Molecular pathogenesis of autosomal dominant polycystic kidney disease. Expert Rev Mol Med 2006; 8: 1-22.
84. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin- 1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471.
85. Zheng R, Wang L, Fan J, Zhou Q: Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway. Cell Biol Int 2009; 33: 926-933.
86. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16: 46-51.
87. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP: Inhibition of mTOR with sirolimus slows disease progression in han:Sprd rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21: 598-604.
88. Zafar I, Belibi FA, He Z, Edelstein CL: Longterm rapamycin therapy in the han:Sprd rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 2009; 24: 2349-2353.
89. Liang G, Yang J, Wang Z, Li Q, Tang Y, Chen XZ: Polycystin-2 down-regulates cell proliferation via promoting perk-dependent phosphorylation of eif2alpha. Hum Mol Genet 2008; 17: 3254-3262.
90. Lee SO, Masyuk T, Splinter P, Banales JM, Masyuk A, Stroope A, Larusso N: Micro- RNA15a modulates expression of the cellcycle regulator CDC25a and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 2008; 118: 3714-3724.
91. Pandey P, Brors B, Srivastava PK, Bott A, Boehn SN, Groene HJ, Gretz N: Microarraybased approach identifies microRNAs and their target functional patterns in polycystic kidney disease. BMC Genomics 2008; 9: 624.
92. Reddy PS, Legault HM, Sypek JP, Collins MJ, Goad E, Goldman SJ, Liu W, Murray S, Dorner AJ, O'Toole M: Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis. Arthritis Res Ther 2008; 10:R127.
93. Wittmann S, Daniel C, Braun A, Vogelbacher R, Shimizu F, Kawachi H, Hugo C: The mTOR inhibitor everolimus attenuates the time course of chronic anti-thy1 nephritis in the rat. Nephron Exp Nephrol 2008; 108: e45-e56.
94. Kramer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H, Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H: Low-dose mTOR inhibition by rapamycin attenuates progression in antithy1- induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 2008; 294: F440-F449.
95. Bijian K, Cybulsky AV: Stress proteins in glomerular epithelial cell injury. Contrib Nephrol. Basel, Karger, 2005, vol 148, pp 8- 20.
96. Cybulsky AV, Takano T, Papillon J, Bijian K: Role of the endoplasmic reticulum unfolded protein response in glomerular epithelial cell injury. J Biol Chem 2005; 280: 24396-24403.
97. Cybulsky AV, Takano T, Papillon J, Khadir A, Liu J, Peng H: Complement c5b-9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells. J Biol Chem 2002; 277: 41342-41351.
98. Inagi R, Kumagai T, Nishi H, Kawakami T, Miyata T, Fujita T, Nangaku M: Preconditioning with endoplasmic reticulum stress ameliorates mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2008; 19: 915-922.
99. Pauley KM, Cha S, Chan EK: MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009; 32: 189-194.
100. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K: Lymphoproliferative disease and autoimmunity in mice with increased mir-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-414.
101. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC: Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel stat3-microRNA cluster 17/92 pathway. Circ Res 2009; 104: 1184-1191.
102. Peairs A, Radjavi A, Davis S, Li L, Ahmed A, Giri S, Reilly CM: Activation of ampk inhibits inflammation in mrl/lpr mouse mesangial cells. Clin Exp Immunol 2009; 156: 542-551.
103. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM: Pras40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007; 25: 903-915.
104. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and akt/pkb. Mol Cell 2006; 22: 159-168.
105. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
106. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
107. Tee AR, Blenis J: mTOR, translational control and human disease. Semin Cell Dev Biol 2005; 16: 29-37.
108. Holz MK, Blenis J: Identification of s6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 2005; 280: 26089-26093.
109. Stolovich M, Tang H, Hornstein E, Levy G, Cohen R, Bae SS, Birnbaum MJ, Meyuhas O: Transduction of growth or mitogenic signals into translational activation of top mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither s6k1 nor rps6 phosphorylation. Mol Cell Biol 2002; 22: 8101-8113.
110. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G: S6k1(-/-)/s6k2(- /-) mice exhibit perinatal lethality and rapamycin- sensitive 5-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent s6 kinase pathway. Mol Cell Biol 2004; 24: 3112-3124.
111. Gingras AC, Raught B, Sonenberg N: mTOR signaling to translation. Curr Top Microbiol Immunol 2004; 279: 169-197.
112. Asnaghi L, Bruno P, Priulla M, Nicolin A: mTOR: A protein kinase switching between life and death. Pharmacol Res 2004; 50: 545-549.
113. Lankat-Buttgereit B, Goke R: The tumour suppressor pdcd4: recent advances in the elucidation of function and regulation. Biol Cell 2009; 101: 309-317.